logo
Search
  • HOME
  • HOT TOPICS
  • LATEST NEWS
  • PRIVACY POLICY
Search

U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug

ADVERTISEMENT
U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug © Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo   AMGN -2.85% Add to/Remove from Watchlist Add to Watchlist Add Position

Position added successfully to:


 
+ Add another position Close JNJ +0.89% Add to/Remove from Watchlist Add to Watchlist Add Position

Position added successfully to:


 
+ Add another position Close

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Amgen (NASDAQ:AMGN)'s biosimilar version of Johnson & Johnson (NYSE:JNJ)'s blockbuster psoriasis treatment, Stelara, for multiple inflammatory diseases.


Despite the FDA approval, Amgen's treatment is expected to be launched in 2025 as part of a legal settlement between the two companies earlier this year to delay the entry of the therapy.



Biosimilars are close copies of complex biological drugs.


Stelara, introduced in 2009, has been J&J's top-selling drug since 2019, with sales reaching $9.7 billion in 2022.


U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug  

RELATED ARTICLE

US mortgage rates have hit a two decade high of 8%
US mortgage rates have hit a two decade high of 8%

Image source, Getty ImagesBy Natalie ShermanBusiness reporter, New YorkAmericans hoping to borrow mo

Consumers’ Pandemic Cash Stash Could Dry Up in 14 Months
Consumers’ Pandemic Cash Stash Could Dry Up in 14 Months

Americans built up quite a nest egg during the pandemic—but at the current rate of spending, it woul

©2025 Finance Guru All Rights Reserved

Privacy Policy

Terms of Service

Contact us at : service